Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alastair M Thompson

Showing results (141-150 of 195) with videos related to

Pageof 20
Sort By:
Journal of the National Cancer Institute|March 6, 2015
Effect of metformin vs placebo on and metabolic factors in NCIC CTG MA.32Pamela J Goodwin, Wendy R Parulekar, Karen A Gelmon, et al.
Cancer Research|July 17, 2004
Small molecule antagonists of the sigma-1 receptor cause selective release of the death program in tumor and self-reliant cells and inhibit tumor growth in vitro and in vivoBarbara A Spruce, Lorna A Campbell, Niall McTavish, et al.
Biorxiv : the Preprint Server for Biology|December 9, 2024
An annotated biobank of triple negative breast cancer patient-derived xenografts featuring treatment-naïve and longitudinal samples throughout neoadjuvant chemotherapyAmanda L Rinkenbaugh, Yuan Qi, Shirong Cai, et al.
Breast Cancer Research and Treatment|April 15, 2023
A phase II study of neoadjuvant atezolizumab and nab-paclitaxel in patients with anthracycline-resistant early-stage triple-negative breast cancerClinton Yam, Elizabeth A Mittendorf, Haven R Garber, et al.
The British Journal of Radiology|January 24, 2024
Evidence-informed recommendations on managing breast screening atypia: perspectives from an expert panel consensus meeting reviewing results from the Sloane atypia projectKaroline Freeman, Alice Mansbridge, Hilary Stobart, et al.
NAR Cancer|July 28, 2021
Erratum: Ribosomal RNA 2' O-methylation as a novel layer of inter-tumour heterogeneity in breast cancerVirginie Marcel, Janice Kielbassa, Virginie Marchand, et al.
Oncotarget|August 18, 2015
Expression profiling of nuclear receptors in breast cancer identifies TLX as a mediator of growth and invasion in triple-negative breast cancerMeng-Lay Lin, Hetal Patel, Judit Remenyi, et al.
Cancer Research|August 13, 2025
An Annotated Biobank of Triple-Negative Breast Cancer Patient-Derived Xenografts Features Treatment-Naïve and Longitudinal Samples During Neoadjuvant ChemotherapyAmanda L Rinkenbaugh, Yuan Qi, Shirong Cai, et al.
NAR Cancer|July 28, 2021
Ribosomal RNA 2'O-methylation as a novel layer of inter-tumour heterogeneity in breast cancerVirginie Marcel, Janice Kielbassa, Virginie Marchand, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 29, 2019
Validation of the DNA Damage Immune Response Signature in Patients With Triple-Negative Breast Cancer From the SWOG 9313c TrialPriyanka Sharma, William E Barlow, Andrew K Godwin, et al.
Pageof 20

Showing results (141-150 of 195) with videos related to

Sort By:
Pageof 20
Journal of the National Cancer Institute|March 6, 2015
Effect of metformin vs placebo on and metabolic factors in NCIC CTG MA.32Pamela J Goodwin, Wendy R Parulekar, Karen A Gelmon, et al.
Cancer Research|July 17, 2004
Small molecule antagonists of the sigma-1 receptor cause selective release of the death program in tumor and self-reliant cells and inhibit tumor growth in vitro and in vivoBarbara A Spruce, Lorna A Campbell, Niall McTavish, et al.
Biorxiv : the Preprint Server for Biology|December 9, 2024
An annotated biobank of triple negative breast cancer patient-derived xenografts featuring treatment-naïve and longitudinal samples throughout neoadjuvant chemotherapyAmanda L Rinkenbaugh, Yuan Qi, Shirong Cai, et al.
Breast Cancer Research and Treatment|April 15, 2023
A phase II study of neoadjuvant atezolizumab and nab-paclitaxel in patients with anthracycline-resistant early-stage triple-negative breast cancerClinton Yam, Elizabeth A Mittendorf, Haven R Garber, et al.
The British Journal of Radiology|January 24, 2024
Evidence-informed recommendations on managing breast screening atypia: perspectives from an expert panel consensus meeting reviewing results from the Sloane atypia projectKaroline Freeman, Alice Mansbridge, Hilary Stobart, et al.
NAR Cancer|July 28, 2021
Erratum: Ribosomal RNA 2' O-methylation as a novel layer of inter-tumour heterogeneity in breast cancerVirginie Marcel, Janice Kielbassa, Virginie Marchand, et al.
Oncotarget|August 18, 2015
Expression profiling of nuclear receptors in breast cancer identifies TLX as a mediator of growth and invasion in triple-negative breast cancerMeng-Lay Lin, Hetal Patel, Judit Remenyi, et al.
Cancer Research|August 13, 2025
An Annotated Biobank of Triple-Negative Breast Cancer Patient-Derived Xenografts Features Treatment-Naïve and Longitudinal Samples During Neoadjuvant ChemotherapyAmanda L Rinkenbaugh, Yuan Qi, Shirong Cai, et al.
NAR Cancer|July 28, 2021
Ribosomal RNA 2'O-methylation as a novel layer of inter-tumour heterogeneity in breast cancerVirginie Marcel, Janice Kielbassa, Virginie Marchand, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 29, 2019
Validation of the DNA Damage Immune Response Signature in Patients With Triple-Negative Breast Cancer From the SWOG 9313c TrialPriyanka Sharma, William E Barlow, Andrew K Godwin, et al.
Pageof 20